Bayer Acquires Two Prescription Dermatology Product Lines from SkinMedica in the U.S.
- Details
- Category: Bayer
Intendis GmbH, which is part of Bayer HealthCare, has signed an agreement to acquire two prescription dermatology product lines from SkinMedica, Inc., a dermatology company based in Carlsbad, CA, USA.
Pfizer Concludes Previously Disclosed Settlement Agreement with U.S. Department of Justice
- Details
- Category: Pfizer
Pfizer Inc today announced that it has finalized a previously reported agreement in principle with the U.S. Department of Justice (DOJ) to settle an investigation regarding past off-label promotional practices related to Bextra, which Pfizer voluntarily withdrew from the market in 2005.
New Analysis of the Pfizer-Sponsored TNT Clinical Trial
- Details
- Category: Pfizer
For patients with established heart disease who were treated with a statin, 18 novel biomarkers including C-reactive protein (CRP) did not predict future cardiovascular events such as heart attack and stroke, according to results of an analysis presented today at the 2009 European Society of Cardiology Congress in Barcelona, Spain. By contrast, traditional lipid risk factors were strong predictors of cardiovascular events.
Abbott Launches Next-Generation XIENCE PRIME(TM) Drug Eluting Stent in International Markets
- Details
- Category: Abbott
Abbott (NYSE: ABT) has announced at the European Society of Cardiology Congress the widespread availability of its next-generation XIENCE PRIME(TM) Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease. XIENCE PRIME, which received CE Mark (Conformite Europeenne) in June, offers a novel stent design and a delivery system designed for greater flexibility and enhanced deliverability.
Phase III Head to Head Trial Showed Ticagrelor Reduced Cardiovascular Death and Heart Attacks
- Details
- Category: AstraZeneca
AstraZeneca has announced results from the phase III head to head trial, PLATO (A Study of Platelet Inhibition and Patient Outcomes), which demonstrate that ticagrelor (BRILINTA™) has achieved greater efficacy in the primary endpoint, reduction of cardiovascular events (CV death, MI, stroke) over clopidogrel (Plavix®/Iscover®) (9.8% vs. 11.7% at 12 months; 16% RRR; 95% CI, 0.77 to 0.92; p<0.001), without an increase in major bleeding (11.6% vs. 11.2%, p=0.43).
Bayer Completes Enrollment into Major Phase III Study with Rivaroxaban (ROCKET AF)
- Details
- Category: Bayer
Bayer Schering Pharma has completed patient enrollment into the Phase III ROCKET AF study (Rivaroxaban Once daily oral direct Factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation). The ROCKET AF study is assessing the efficacy and safety of rivaroxaban (Xarelto®) 20 mg once-daily, a novel oral, direct Factor Xa inhibitor, compared to the current standard of care, warfarin, a vitamin K antagonist (VKA) dose-adjusted, for the prevention of stroke and non-CNS systemic embolism in patients with Atrial Fibrillation (AF).
Bayer Completes Enrollment into Major Phase III Study with Rivaroxaban
- Details
- Category: Bayer
Bayer Schering Pharma has completed patient enrollment into the Phase III ROCKET AF study (Rivaroxaban Once daily oral direct Factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation). The ROCKET AF study is assessing the efficacy and safety of rivaroxaban (Xarelto®) 20 mg once-daily, a novel oral, direct Factor Xa inhibitor, compared to the current standard of care, warfarin, a vitamin K antagonist (VKA) dose-adjusted, for the prevention of stroke and non-CNS systemic embolism in patients with Atrial Fibrillation (AF).
More Pharma News ...
- Studies Published in The Lancet Show Roflumilast Improves Lung Function and Reduces Exacerbations
- Abbott to Collaborate With Pfizer Inc on Companion Diagnostic Test
- Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy
- Health Canada Approves Abbott's XIENCE V(R) Drug Eluting Stent
- Lilly Reports on Outcome of Phase III Study of Arzoxifene
- Novartis drug Femara® is superior to tamoxifen after breast cancer surgery
- Nycomed reports sustained momentum in second quarter 2009